Perspectives

How does this study impact clinical practice?

• Patients who are switched from erenumab to galcanezumab treatment report similar improvement in migraine symptoms.
• The most common reason for patients to discontinue erenumab or galcanezumab treatment is lack of efficacy, but insurance issues and side effects are also contributory factors.